1. Home
  2. AKRO vs DAR Comparison

AKRO vs DAR Comparison

Compare AKRO & DAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • DAR
  • Stock Information
  • Founded
  • AKRO 2017
  • DAR 1882
  • Country
  • AKRO United States
  • DAR United States
  • Employees
  • AKRO N/A
  • DAR N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • DAR Packaged Foods
  • Sector
  • AKRO Health Care
  • DAR Consumer Staples
  • Exchange
  • AKRO Nasdaq
  • DAR Nasdaq
  • Market Cap
  • AKRO 4.5B
  • DAR 5.1B
  • IPO Year
  • AKRO 2019
  • DAR 1994
  • Fundamental
  • Price
  • AKRO $54.34
  • DAR $34.92
  • Analyst Decision
  • AKRO Buy
  • DAR Strong Buy
  • Analyst Count
  • AKRO 10
  • DAR 7
  • Target Price
  • AKRO $73.56
  • DAR $44.71
  • AVG Volume (30 Days)
  • AKRO 1.7M
  • DAR 2.4M
  • Earning Date
  • AKRO 11-07-2025
  • DAR 10-23-2025
  • Dividend Yield
  • AKRO N/A
  • DAR N/A
  • EPS Growth
  • AKRO N/A
  • DAR N/A
  • EPS
  • AKRO N/A
  • DAR 0.67
  • Revenue
  • AKRO N/A
  • DAR $5,843,771,000.00
  • Revenue This Year
  • AKRO N/A
  • DAR $5.12
  • Revenue Next Year
  • AKRO N/A
  • DAR $4.11
  • P/E Ratio
  • AKRO N/A
  • DAR $51.12
  • Revenue Growth
  • AKRO N/A
  • DAR N/A
  • 52 Week Low
  • AKRO $21.34
  • DAR $26.00
  • 52 Week High
  • AKRO $58.40
  • DAR $43.49
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 68.92
  • DAR 63.53
  • Support Level
  • AKRO $54.10
  • DAR $33.96
  • Resistance Level
  • AKRO $54.37
  • DAR $35.12
  • Average True Range (ATR)
  • AKRO 0.18
  • DAR 1.17
  • MACD
  • AKRO -0.22
  • DAR 0.20
  • Stochastic Oscillator
  • AKRO 89.00
  • DAR 91.56

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About DAR Darling Ingredients Inc.

Darling Ingredients Inc develops and manufactures sustainable ingredients for customers in the pharmaceutical, food, pet food, fuel, and fertilizer industries. It collects and transforms all aspects of animal by-product streams into ingredients, including gelatin, fats, proteins, pet food ingredients, fertilizers. Also, the company recovers and converts used cooking oil and bakery remnants into feed and fuel ingredients. Darling has three primary business segments which are feed ingredients contributing the majority of revenue, food ingredients, and fuel ingredients. It provides grease trap services for food businesses and sells various equipment for collecting and delivering cooking oil. The company derives the majority of its revenue from customers in North America.

Share on Social Networks: